Boston Scientific Picks Up LifeCell's AlloDerm After Dropping ProtoGen
This article was originally published in The Gray Sheet
Executive SummaryBoston Scientific's decision to stop selling the ProteGen synthetic urethral sling helped the firm gain worldwide marketing and distribution rights to LifeCell's AlloDerm acellular tissue matrix for urological and gynecological applications.
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.